Physician profile
Ryan Christopher Barnes
NPI 1649869645
$3,921.66
in general payments reported to CMS, 2019-2025
29 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.17 · 2022: $620 · 2023: $1,143 · 2024: $468 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,266.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.69 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $676.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $610.78 | 2022-2025 | |
| Exact Sciences Corporation | $222.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $151.83 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $126.74 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $125.87 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boston Scientific Corporation | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $116.11 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Ironshore Pharmaceuticals INC. | $106.04 | 2022-2023 | Jornay Pm |
| Corcept Therapeutics | $96.56 | 2025 | Korlym |
| Amgen INC. | $85.04 | 2023-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.80 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $68.79 | 2023-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $66.83 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $61.12 | 2025 | Gemtesa, Myfembree |
| Gilead Sciences, INC. | $46.60 | 2025 | |
| Lundbeck LLC | $43.91 | 2024 | Vyepti |
| Neos Therapeutics, LP | $42.14 | 2023-2024 | Adzenys Xr-Odt |
| Bayer Healthcare Pharmaceuticals INC. | $41.95 | 2025 | |
| Idorsia Pharmaceuticals US INC | $37.67 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $35.17 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $23.52 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $22.94 | 2022 | |
| Axsome Therapeutics, INC. | $19.26 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $19.23 | 2023 | Krystexxa |
| Nevro Corp. | $15.99 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.